Tag Archives: oulu wellness institute

New website for OWI and Wellness Business Blog

We have updated our website. You can find it at http://www.owi.fi/

You can also find our blog in a new address at http://www.owi.fi/blog/

 

Olemme uudistaneet webbisivumme. Uudet sivut löydät täältä: http://www.owi.fi/

Myös Wellness Business Blog löytyy uudesta paikasta täältä: http://www.owi.fi/blog/

 

FDA ohjeistaa lääkinnällisten mobiilisovellusten kehittäjiä

FDA ohjeistaa lääkinnällisten mobiilisovellusten kehittäjiä

Teksti ja kuva: Terhi Holappa, Usbimed Oy

Terveyden mobiilisovellukset – kasvava trendi

Terveyteen liittyvien (mHealth – Medical, Health & Fitness) mobiilisovellusten historia on lyhyt, mutta niiden käyttö on kasvanut räjähdysmäisesti viime vuosina. Vuonna 2010 MobileHealthNews1 kertoi, että saatavilla oli noin 5000 älypuhelimeen toteutettua terveyteen liittyvää mobiilisovellusta. KaiserHealthNews2 raportoi 40 000 sovellusta kesäkuuhun 2012 mennessä. Jeffrey Shuren (FDA:n Center for Devices and Radiological Health (CDRH) johtaja) mukaan maailmalla tulee olemaan vuonna 2015 jopa 500 miljoonaa älypuhelinkäyttäjää, joilla on jokin terveyteen liittyvä sovellus laitteessaan3.


FDA sääntely terävöityy

Kaupallisille yleiskäyttöisille mobiilialustoille toteutetuilla mHealth sovelluksilla voi olla merkittävä vaikutus terveydenhuollon organisoitumiseen, sairauden ennaltaehkäisyyn sekä omahoitoon. Lääkärit voivat monitoroida potilaiden terveydentilaa etäteitse, potilaat voivat hallita omaa terveyttään ja hyvinvointiaan sekä saada myös hyödyllistä terveystietoa ajasta ja paikasta riippumatta. Tämä kehityssuunta voi johtaa esimerkiksi siihen, että kuluttaja luottaa mHealth sovelluksen antamaan tietoon lääkärillä käynnin sijasta. Viranomaissääntelyn tarve on ilmeinen tällä harmaalla alueella.

Yhdysvaltojen Food and Drug Administration (FDA) pyrkii pysymään mukana tässä kehityksessä. Syyskuussa 2013 virasto julkaisi ohjeen, joka auttaa tunnistamaan lääkinnälliseksi laitteeksi luettavat älypuhelin- tai tablettisovellukset (Mobile Medical Application), jotka kuuluvat FDA sääntelyn piiriin. Lääkinnällisiksi mobiilisovelluksiksi luokitellaan ohjelmistot, jotka toimivat yleiskäyttöisillä mobiilialustoilla ja tukevat samaa käyttötarkoitusta kuin perinteisemmät lääkinnälliset laitteet.

Ensimmäinen FDA:n luvan (510 (k) clearance) saanut lääkinnällinen mobiilisovellus tuli markkinoille vuonna 2011. Tähän mennessä FDA on hyväksynyt noin 100 mobiilia lääkinnällistä sovellusta ja näistä 40 viimeisen kahden vuoden aikana.

Turvallisuusriskit sääntelyn keskiössä

FDA sääntelyn painopiste on mobiilisovelluksissa, jotka saattavat aiheuttaa merkittävämmän riskin terveydelle. Suurimman osan sovelluksista FDA luokittelee kuitenkin pienen riskin omaaviksi. Niitä sääntely ei kosketa. Jeffrey Shuren mukaan3, luodun lähestymistavan ei ole tarkoitus tukahduttaa innovointia vaan varmistaa kuluttajan turvallisuus sekä taata kuluttajien parissa samanlainen luottamus kuin minkä he omaavat perinteisempiä lääkinnällisiä laitteita kohtaan.

Esimerkit selkiyttävät jaottelua

Lääkinnällisenä laitteena ja FDA sääntelyn piiriin kuuluvina pidetään ohjeen mukaan esimerkiksi sovelluksia, jotka kykenevät tunnistamaan epänormaaleja sydämen rytmejä ja lähettämään reaaliajassa lukemia lääkärille, monitoroimaan elintärkeitä elintoimintoja ensihoitotilanteessa, muuttamaan älypuhelimen ultraääni laitteeksi tai auttamaan diabeteksesta kärsiviä monitoroimaan heidän verensokeriarvojaan (taulukko 1).

Lääkinnällisen laitteen lisälaite taas voi olla esimerkiksi sovellus, jonka avulla lääkäri tekee diagnoosin katselemalla lääketieteellistä kuvaa yleiskäyttöisellä mobiilialustalla sijatsevasta PACS järjestelmässä (picture archiving and communication system). Tämän tyyppiset sovellukset kuuluvat myös FDA sääntelyyn piiriin (taulukko 1).

“ECG machine that diagnoses heart rhythms is still an ECG machine whether it is the size of a breadbox or the size of a smartphone,” Jeffrey Shuren says3. “It’s not about the platform, it’s about the functionality

Taulukko 1. Mobile medical apps requiring FDA registration4

Apps using sensors connected  to ECG equipment Apps using sensors to amplify sounds from electronic stethoscopes
Apps that measure physiological parameters used in diagnoses Apps used to alter infusion pump settings or functions
Apps that calibrate cochlear implants and hearing aids Apps connecting to nursing stations in order to display medical device data to
mobile platforms
Apps connecting to bedside monitors and transferring patient data to doctors or
nurses
Apps connected to perinatal monitoring equipment to enable remote labor monitoring

Älypuhelinsovellukset, joita lääkärit tai potilaat käyttävät verenpaineen seurannassa täyttävät kyllä lääkinnällisen laitteen määritelmän, mutta eivät tästä huolimatta kuuluu FDA sääntelyn piiriin tämän hetkisen ohjeen mukaan. Sovellus voi edistää potilaan vastuuta omasta terveydestään ja omata terveysvaikutuksia mutta FDA näkee tämän tyyppisten sovelluksien turvallisuuteen liittyvän riskin olevan pieni (taulukko 2).

Taulukko 2. Mobile medical apps the FDA will NOT regulate4

Apps providing behavioral techniques to reduce psychiatric symptoms Apps providing educational or motivational data for physical therapy or smoking
cessation patients
Tools for tracking asthmatic episodes and inhaler use Apps that suggest possible medical conditions based on user input
Apps that keep track of users’ medication dosages and schedules Apps to collect and share blood pressure data

FDA sääntelyn piiriin kuuluvien mobiilien lääkinnällisten sovelluksien markkinoille saattamista koskee samat menettelytavat kuin perinteisempiä lääkinnällisiä laitteita. On huomattava, että sääntely ei ulotu kaupallisiin alustoihin itsessään eikä myöskään mobiilisovellutusten jakelijoihin kuten Google Play Store ja Apple iTunes App Store. Jakelijoiden ja kehittäjien tulee kuitenkin tehdä yhteistyötä FDA ohjeen mukaan4.

Mitä isot edellä sitä pienemmät perässä

FDA on säännellyt lääkinnällisiä laitteita jo vuodesta 1976 lähtien. USA on lääkinnällisten laitteiden ja ohjelmistojen markkinajohtaja maailmassa. Nyt julkaistu ohje on merkittävä
päänavaus kaupallisille, yleiskäyttöisille mobiilialustoille toteutettujen sovellusten sääntelyn täsmentämiseksi. Tämä tulee näkymään entistä merkittävämmin myös EU talousalueella jatkossa.

Lähteet:

1 MobileHealthNews State of Industry report 2010 http://mobihealthnews.com

2 Gold, Jenny. FDA Seeks To Tame Exploding Medical App Market (26.6.2012)http://www.kaiserhealthnews.org

3  Shuren, Jefrey. FDA issues final guidance on mobile medical apps (23.9.2013) http://www.fda.gov/newsevents/newsroom/

4 Mobile Medical Applications.
Guidance for Industry and Food and Drug Administration Staff (25.9.2013) http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM263366.pdf

Terveysteknologian myrskyvaroitus

Terveysteknologian myrskyvaroitus

Teksti ja kuva: Eeva Kiuru

Kirjoittaja on Oulu Wellness Instituuttisäätiön toiminnanjohtaja. Twitter @eevakiuru

Amerikkalainen huippututkija, sähköisen terveydenhuollon pioneerilääkäri Eric Topol
vieraili viime viikolla Helsingissä. Sitran järjestämässä Tulevaisuuden terveys 2020 -seminaarissa yli 600 suomalaista terveydenhuollon asiantuntijaa kuunteli hämmentyneenä, kun Topol vyörytti esityksessään hengästyttävän määrän terveyden innovaatioita, joka tulevat muuttamaan maailmaa.

Digitalisaatio muuttaa rajusti terveydenhuollon toimintamalleja. Yhä enemmän ihmiset itse keräävät mittaustietoja. Tämä on hyvä asia, sillä tunnetusti mitä enemmän ihmiset itse aktiivisesti osallistuvat sairauden hoitoon, sitä parempia ovat myös hoitotulokset. Mittausten
paikkasidonnaisuus häviää. Ketterät etäyhteydet korvaavat valtaosan läsnävastaanotoista.

Lääkäri ei ole enää ainoa tiedon lähde. Hänestä tulee potilaiden kumppani ja valmentaja. Moni lääkäri on varmasti jo nyt ymmällään aktiivisen, mittaustuloksia ja omadiagnooseja mukanaan tuovan potilaan edessä.

Terveysteknologian kehittäjäyhteisöt ovat ennennäkemättömällä vauhdilla alkaneet luoda uusia tuotteita markkinoille. On kiehtovaa, kuinka nopeasti yhteisö on tarttunut erityisesti älypuhelinalustan mahdollisuuksiin. Tärkeimmät elintoiminnot – verenpaineen, verensokerin,
veren happipitoisuuden ja EKG:n – voi jo nyt mitata omatoimisesti älypuhelimen lisälaitteilla.

Kuluttajilla on entistä enemmän mistä valita 50-vuotislahjoja: unimittari, aktiivisuusranneke tai korvavalo. BestBuy-kuluttajaelektroniikkakaupassa on kokonainen osasto mitä erilaisempia
terveyden mittareita. Kuluneen kesän aikana on lanseerattu kymmenittäin uusia terveysteknologiatuotteita vauvojen aktiivisuusmittareista muodikkaisiin kosketusnäyttöisiin terveyskelloihin.

Sokerina pohjalla on IBM:n projekti Watson. Tohtori Supertietokone, joka diagnoosia tehdessään prosessoi 2 miljoonaa sivua potilaskertomuksia alle 3 sekunnissa. Watsonin diagnosointikapasiteetti yhdistettynä kuluttajan älypuhelimiin on aikamoinen tulevaisuuden palvelumalli.

Terveysteknologian kehittäjiltä on tullut myrskyvaroitus. Jos sinulla on terveyteen liittyvä kehittämisidea, sen toteuttamisen aika on juuri nyt.

Kirjoitus on julkaistu 18.9.2013 painetussa ja sähköisessä Oululehdessä.

Health tech accelerators – powerhouses of health innovations

Health tech accelerators – powerhouses of health innovations

Text and photo: Eeva Kiuru, Oulu Wellness Institute

This blogpost concludes our miniseries of funding advise to health tech innovators. In our previous posts we have collected list  of all active investors in the category of health, wellness and life science in Finland, Scandinavia, Europe and the US. In this final post we wrap up a
collection of interesting accelerator programs within health technology domain.

Who knew 5 years ago what kind of accelerator boom would take place in the startup scene in just a few years time? According to National Business Incubation Association (NBIA) there are now over 1,250 incubators in the United States and about 7,000 business incubators worldwide.

The whole idea of accelerators is to get startup founders exposure to networks with domain expertise and funding in order to get the business faster on the right track. Most of the accelerators are generic with a broad (mobile, web) domain focus.

Life science is a great example of a challenging industry where it makes sense to build industry-specific accelerators to speed up the development. Life science accelerators often have strong connection to medical faculties or medical centers as well as other key stakeholders in the life science industry, such as regulation and reimbursement experts, mentors, investors and networks. Most importantly accelerators have access and connections to early adopting customer prospects.

Accelerator services often include affordable office space, access to laboratory facilities, access to peers, support services, coaching and even seed funding. Other services include for example expert lectures, advisor and faculty office hours, workshops, networking events, and brokered customer meetings.

Many accelerators are non-profits funded by grants from government or they are funded by corporations and vc’s. As a return, accelerators’ funding partners get an early access to pre-screened dealflow, access to bubbling innovations and talent pool. By connecting with the vibrant health startup scene, they also get positive visibility for their corporate brand. Some accelerators take equity in the chosen accelerator startups. In the current accelerator boom
it is important for a startup to screen the track records of the accelerator they plan to apply for.

Here is our selection of interesting incubators, accelerators and co-working spaces for a seed-stage health and life science startup founder:

Alchemist Accelerator (Menlo Park, Calif.) is a venture-backed initiative focused on accelerating technical seed-stage enterprise startups, whose revenue comes from enterprises, not consumers. They select twice a year 10 teams for their 6 month program and $ 28 k funding. Selected startups must locate at the Bay Area but are not required to move in the Alchemist premises. They can locate where they choose in order to create their own company culture. Alchemist is not a pure life science accelerator but an interesting alternative also for a technical health startup with b-to-b focus.

BioCurious (Sunnyvale, Calif.) is a hackerspace for biotech with a mission to make innovations in biology accessible, affordable, and open to everyone. It is a co-working, training and meeting
place for citizen scientists, hobbyists, activists, and students. It is a complete working laboratory and technical library for entrepreneurs to cheaply access equipment and materials.

Blueprint Health (New York City, New York) offers twice a year an intensive three-month accelerator program to help healthcare entrepreneurs find customers and capital. The foundation of the program is a community of over 150 healthcare entrepreneurs, investors and industry executives. Accepted startups receive for example $20,000 in cash and an office space at Blueprint Health SoHo office. In exchange for the funding, support and mentorship, Blueprint Health receives a 6% equity stake in the accelerated company. Blueprint Health has a broad healthcare focus but does not include med tech or drug development.

Digital Health New York’s (New York City, New York) focus areas are care coordination, analytics, message alerts and patient engagement. Selected startups get access to clinical and technology provider organizations including hospitals, long-term care providers, community health centers, and primary care providers. They also get access to interoperability work group and a network of healthcare leaders, successful entrepreneurs, and investors. Each selected company will receive up to $300,000 of capital (convertible note).

Fogarty Institute for Innovation (Mountain View, Calif.) aims to create an environment where one can cost effectively develop technology that directly benefits patients. It is an educational
nonprofit offering three programs for different aspects of medical technology innovation (Innovation/Cultivation, Clinical Research/Validation and Outreach/Education).  Located on the campus of El Camino Hospital, the Fogarty Institute for Innovation includes laboratory and engineering space where physicians and engineers collaborate. Since 2007 four hand-picked applicants have received direct, sustained support in the form of facilities, ongoing mentoring and/or technology development costs.

Healthbox (Boston, Chicago, and London) brings together entrepreneurs, strategic partners, industry experts and investors to tackle real healthcare challenges. They look for healthcare
technology and technology-enabled service startup founders who address a specific and pressing challenge in the healthcare industry. They are interested in for example, improving patient engagement, provider effectiveness or preventative health and wellness. Entrepreneurs selected to participate in the 16-week program receive $ 50.000 seed money and support designed to address the challenges unique to starting a business in healthcare. In exchange for the program benefits, startups provide Healthbox with 7% equity.

Health XL  (Dublin and London) program begins in February of each year and focuses on
startups within digital health technology. The program has over 150 mentors and also works closely with healthcare industry, who sponsors the program. Health XL’s focus is in the following domains: direct medical solutions, personalization, patient compliance, prevention and participatory health solutions, health economics and integrated solutions.

More Disruption Please (MDP) is Athena Health’s innovation and partnership program aimed at entrepreneurs, health care IT companies, investors and thought leaders—anyone who shares their vision of changing the status quo in health care through openness and connectivity of disruptive solutions. With the program, AthenaHealth connects new innovators with their 35.000 health service providers. The company will ask neither for a fee nor equity, only for a discount for its clients. Also, MDP wants to give their partners a “go-to-market in a box” via their cloud-based network and integration into medical providers’ workflow.

RockHealth (San Fransisco, Calif.) was the first seed accelerator exclusively targeted for health startups. RockHealth takes in two classes a year. They provide capital ($100K convertible note), office space, mentorship, and operational support to high-potential, early stage, pre-vc entrepreneurs working on ideas in health. They focus on the disruptive edge of healthcare and look for themes like quantified self, EMR interoperability, provider-patient relationship, home
health, home aging, big data, modern analytics, enhanced care delivery, cost transparency, clinical trial modernization and smart health sensors and gadgets. Ideas should be addressing large problems in the healthcare system, with a business model that is sustainable and scalable.

We hope you found this resource useful. New programs and accelerators are born almost on a weekly basis all over the world so this is not trying to be a comprehensive list. Rather it is a quick look at what kind of alternatives there are available for the early stage health startup wanting to speed up their business.

Health, wellness and life science investors in Europe and USA

Health, wellness and life science investors in Europe and USA

Text by Eeva Kiuru and Veera Virta, Oulu Wellness Institute
Photo by Veera Virta

This is the third blogpost in our series introducing investors in health, wellness and life science. In previous parts we have collected investors in Finland and in Scandinavia. Now it is time to introduce investors in Europe and US. Since corporate venturing has started to play important role is life science investing, we have also included a list of some corporate investors in this domain.

___

Aberdare Ventures is investing in disruptive digital healthcare companies who aim to cut the unbearable cost of current healthcare. They see new technologies, such as connectivity, analytics, and portability; smart sensors and connected implantables; fast and inexpensive analyses of genes and proteins, the drivers of the change in healthcare. They are located in San Fransisco.


Advent Ventures is a growth and venture capital investor in market-leading tech and life science businesses. Their investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics. They invest predominantly in early and mid-stage life science companies in Europe and US.

AESCAP is a venture capital company investing in private medical companies in Europe. Their focus is in high-potential companies that work in the fields of diagnosis and treatment of human diseases with realistic product opportunities. The office is in Amsterdam.

Aravis is a Swiss hands-on investor and within life science their focus is on biopharmaceuticals, medical technology and biotechnology companies. They operate in Europe, Asia and North America, with offices in Zurich.

Ariadne Capital is an early-stage investor with a focus on enabling technologies and tools which are transforming established businesses and creating the digital ecosystem of health and lifestyle. They are based in London.

BB Biotech Ventures focuses on emerging companies developing and marketing drugs and medical devices. They primarily focus on product-driven, clinical-stage companies.

Earlybird VC manages over 20 institutional investors’ funds and has invested in over 70
companies. They focus in startups based in Europe and their investment focus areas include medtech. The offices are located in Berlin, Munich and Milano.

Endeavour Vision is a venture and growth capital firm providing expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. They operate in Europe and US and invest in early to expansion stage companies including spin-offs and restarts.

ED Venture‘s primary activity is investing in and nurturing start-ups, with a focus on health care, human capital and aerospace. Overall, the chairman of ED Ventures, Esther Dyson, is fascinated by new business models, new technologies and new markets (both economically and politically).

Forbion Capital Partners invests in life science and biomedical technology companies that are developing world-class drugs and technologies. They focus in late stage preclinical and early stage clinical product development programs. They have offices in Naarden, Netherlands and Munich, Germany.

Gimv invests in life science, medtech, health and care services companies operating in European market. Offices are in Antwerpen, Paris, Munich and Hague.

Index Ventures is one of the early venture firms in Europe, and they are dedicated to building world-class information technology and life science companies. They invest globally in companies with European focus, and their offices are located in Geneva and London. The initial investments focus in on series A and B rounds.

Khosla Ventures is a high profile investor interested in sevaral disruptive sectors including consumer health. They focus on early stage crazy ideas, black swans and unusual approaches with an unfair competitive advantage in their early and growth phases.

Life Science Partners, LSP, is one of the largest specialized healthcare and biotechnology investment firms. They operate in Europe and US with offices in Amsterdam, Munich and Boston. They invest in variety of areas in healthcare and biotechnology, including drug discovery and development, medical devices, diagnostics, IT-based solutions, industrial biotech and bio materials. The focus in on start-up companies in need of first venture funding but they invest also in later-stages.

Merieux Development is a healthcare investment company. Their main objectives are to identify scientific and technological innovations and support entrepreneurs and companies which potentially will contribute to the medicine of the future. Their target is to have 12 SME’s at different stages of development by 2014 in their portfolio. They operate in Europe, North America, India and China, with office in Lyon, France.

MVM Life Science invests in emerging, early and later stage, healthcare companies with focus on venture capital and growth equity investments. Currently portfolio companies are located in Europe, Israel and US. In life sciences they focus on platforms and products, discovery and development and devices and drugs.

NBGI Ventures is a venture capital fund investing in medical technology companies. Primarily, they invest in EU countries and in companies of all stages from seed to development.

NEA is investor focusing on three key domains—information technology, healthcare and energy technology in the early and growth phases. They operate in US, India and China.

Sofinnova Partners is venture capital firm based in Paris. It invests throughout Europe in life science and clean energy start-ups, early stage companies and corporate spin-offs. It is often the first institutional investor in round A financing.

TPG Biotech is the life science venture investment arm of TPGSM (formerly known as Texas Pacific Group), a global private investment firm. TPG Biotech supports physicians, scientists and entrepreneurs who are building innovation-based businesses in the life sciences. TPG Biotech invests across life science sectors, geographies and stages.

Wellington Partners makes early-stage and growth investments in life science and technology companies. Their focus in life science is in medtech, diagnostics, therapeutics and industrial biotechnology.

Vesalius BioCapital offers venture capital to young, innovative European life science companies and invests human health related companies. The focus is on therapeutics, medical devices, diagnostics, and novel food applications and in companies of all stages of development.

Corporate investors

Ascension Health Ventures (AHV) is a strategic healthcare venture fund with $550 million in capital and nearly 300 acute care hospitals and numerous other healthcare related facilities as limited partners. Besides financial return, investment criteria include fit with strategic priorities of AHV’s limited partners’ health systems and potential to improve clinical outcomes, reduce costs, and/or enhance the experience of patients, families and caregivers. Investment focus is in
healthcare information technology and services, and medical devices and diagnostics.

BlueCross BlueShield Venture Partners (BCBSVP) is corporate venture fund sponsored by the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. The fund invests in technologies, products and services in the healthcare industry that promote efficiency, lower costs, and provide more consumer options. Investments are made from seed through growth stages in US based companies. Focus areas are health IT, informatics, administration and back office, health programs, consumer driven solutions and healthcare finance.

Boehringer Ingelheim Venture Fund’s objective is to search significant enhancements in patient care through innovative and pioneering science. They look globally for groundbreaking therapeutic approaches and technologies that have the potential to advance patient care and meet unmet medical needs. They make initial investments in seed or series A funding.

Merck Global Health Innovation Fund (GHI) is building a portfolio of investments in six focus areas that are outside of Merck’s core pharmaceuticals, vaccines, consumer products, and animal health businesses. GHI’s goal is to grow emerging health care solutions into meaningful businesses. Companies they invest in typically have current revenues, a strong business plan and high growth potential. Focus areas include flexible access, health intervention, personalized medicine, health productivity enablers, health infromatics and analytics and heath data liberation.

Qualcomm Ventures (QCV) is investment arm of Qualcomm Inc. They focus on disruptive early stage companies across a wide range of sectors, including healthcare. Their healthcare focused fund is Qualcomm Life. It specifically focuses on investing in venture-backed wireless health start-ups that will help accelerate the Qualcomm 2net Platform commercialization. The areas of specific interest to the fund range from personal wellness to disease management. Investments are made in areas such as body worn or implantable biosensors or devices for vertically focused applications such as chronic disease care, medication adherence, and fitness or wellness; integrated system providers that do remote diagnosis, monitoring or specialize in independent living; mobile software health IT applications; and health informatics/analytics

West Health Innovation Fund’s mission is to lower health care costs. They invest in companies that are developing health care technologies or services that have the potential to substantially lower the cost of health care delivery. The Fund targets early stage opportunities with a strong preference for pre-commercial and early commercial companies. They invest in innovations in the following areas: advancing cost-effective, cost-saving models of care, creation of efficient medical marketplace, promotion of actionable health care policy and health care data liberation.

This was quite a long list of potential investors. Life science and especially it’s new frontier, digital health and health IT is bubbling right now.  We wanted to do our share and make the funding opprtunities better visible for entrepreneurs. We are sure there are plenty of other investors currently active or becoming active in this field since this is a growth area and many traditional investors are already kicking tires of health tech and health IT.

And by the way, may we recommend you also have a look also at AngelList. There you can find  investors with specific keywords that fit exactly your funding needs.

___

In the next and final blogpost of this series we will focus on collecting the health tech and life science business accelerators. As always, please comment if we missed something you think should be added here. We would love to hear your comment to make sure this a valuable resource for you.

Health, wellness and life science investors in Scandinavia

Health, wellness and life science investors in Scandinavia

In the first part of the series introducing health, wellness and life science investors we introduced Finland-based investors. This second part of the series consists of introductions of investors based and investing in Scandinavia. The information here is gathered from the websites and introduces only the very basics of each investor, so use the links and go find out more!

_______

BirkVenture is a Scandinavian venture company that offers venture capital to companies and entrepreneurs in life sciences. Their office is in Oslo. In their investments, they focus in pharmaceuticals, biotechnology, diagnostics, medical devices and instruments, and consumer
health, and they look for attractive, long-term business cases and companies in their early stages.

HealthCap is a family of multi stage venture capital funds, investing globally in life sciences, with offices in Stockholm and Lausanne, Switzerland. They invest in the commercialization of innovations in medical science, focusing in pharmaceutical, biotechnology and medical technology companies. The investments are made in early-stage opportunities as well as in
more mature companies.

Incitia Ventures  is an independent Nordic VC fund manager based in Oslo. They invest in technology companies in the start-up and expansion phase within broad range of technology sectors. Incitia Ventures has hands-on involvement in companies so they invest in and nurture only a few investments at a time.

Innovationskapital  is an independent early stage venture capital firm for innovative growth companies in the Nordic region. They focus in early-stage companies in the areas of ICT, healthcare and life sciences.

Innoventus’ mission is to develop novel technology concepts and transform those into objects of visible and measurable commercial value. They invest in biotech and life science companies in the phase where technology ventures are too immature to meet traditional investment criteria. The geographic area of their investments is not defined, the headquarters are in Uppsala, Sweden.

Lundbeckfond Ventures is a venture fund investing in life science companies. It is owned by Lundbeck Foundation. The focus of their investments is in clinical pharmaceuticals and biopharmaceuticals, medtech, diagnostics, and healthcare service companies in northern Europe.

Novo Seeds is a life science supporting program that consists of a pre-seed fund and a seed fund. Their aim is to identify and develop into successful businesses the unexplored commercial potential in the academic and early stage applied research projects at universities and biotech companies in Scandinavia. See also other Novo Group investors, Novo Ventures and Novo Growth Equity.

NXT2B is a privately owned venture capital company with offices in Uppsala, Sweden. They invest with long term commitment in healthcare, medical device, and specialty pharmaceutical companies in their early phases. The focus is in projects with high scientific quality with reasonable business opportunities.

SLS Invest is a Scandinavian investor focusing in life science companies in Scandinavia. They invest in small and mid-sized companies in late product development, launch or product line extension phases.

Sunstone Life Science Ventures is a European investor based in Copenhagen. They invest in early-stage life science companies with focus in therapeutics, medtech, and diagnostics. The point of entry of the investment depends on the type of life science opportunity. Their geographic focus is especially in Nordic countries, Germany and Switzerland.

Vanadis Capital combines life science business knowledge, hands-on operational expertise and medical background in providing human and financial resources in acceleration of product validation, end-user alignment, market access and early growth. They focus on biotechnologies,
diagnostics, medical devices and services, and pharmaceuticals in northern Europe.

_______

Hopefully these northern investor links are useful to you. Let us know if we missed someone who should be on the list. In the next blogpost we turn the attention to investors acting in wider
European scale, and finally in the fourth post we will wrap up the different healthtech business accelerators.

Kaleva: Hyvinvointiteknologian buumi kiihtyy – lääkärit määräävät hoidoksi kännykkäsovelluksia

Kaleva: Hyvinvointiteknologian buumi kiihtyy - lääkärit määräävät hoidoksi kännykkäsovelluksia

Kalevassa tänään Pasi Klemettilän artikkeli Hyvinvointiteknologian buumista.Esimerkiksi älypuhelimesta on tullut maailmalla perusmoottori monenlaisille hyvinvointituotteille, sanoo Oulu Wellness Instituuttisäätiön (OWI) toiminnanjohtaja Eeva Kiuru.

Katso juttu eKalevasta tai päivän painetusta Kalevasta.